LONDON (Reuters) – New cases of rare and severe blood clots have not been reported in the UK in recent weeks following the vaccine against Covit-19 by the AstroZeneca vaccine, scientists told Britain this Wednesday following a decision to restrict the use of people under the age of 40.
Vaccine-induced thrombotic thrombocytopenia (VITT) is a combination of blood clots and low platelet counts, a rare side effect of the Kovid virus vector vaccine produced by Astrogenega and Johnson & Johnson.
The increase in side effects in adolescents has prompted many countries to impose age restrictions on the astrogenic vaccine.
About 85% of people with rare blood clots after being vaccinated with AstraZeneca in the UK are under the age of 60, although the elderly are given more vaccines, which is one of the absolute hallmarks of this syndrome.
According to previous estimates, the incidence was 1 in 50,000 in people under the age of 50, and the researchers said that this would help predict the benefit-risk calculation of the vaccine.
Hematologist Sue Boward, a consultant at Oxford University Hospital who led the study, said the incident affected young people who are generally healthy and that it was especially dangerous if there was bleeding in the brain.
But he said the initial increase in side effect cases had slowed with the impact of the UK decision to provide alternative vaccines for those under 40 in May.
“We have not seen any new cases in the last four weeks, which is a huge relief,” he told reporters.
The article was published in the New England Journal of Medicine.
(Report by Alistair Smout)